NextPoint

NextPoint Therapeutics, Inc., founded by MPM Capital, has assembled a team of proven drug developers to build a broad strategic pipeline of first-class immunotherapies, aiming to provide new options for cancer patients. The scientific founders of NextPoint recently discovered a novel checkpoint axis, independent of PD-1/L1, which is present at high levels in many difficult-to-treat cancers. This revolutionary discovery represents a previously unknown gateway for modulating both adaptive and innate immune systems to detect and destroy cancer cells.